Approved Treatments
Treatment for Ebola virus disease combines foundational supportive care with FDA-approved antiviral therapies. Outcomes have improved dramatically since the pre-treatment era.
Supportive Treatment (All Strains)
Supportive care remains the foundation of Ebola treatment and significantly improves survival:
- Intravenous fluids to combat severe dehydration from vomiting and diarrhea
- Electrolyte replacement
- Blood pressure management
- Treatment of secondary infections
- Oxygen therapy when needed
- Pain and symptom management
Early initiation of supportive care is strongly associated with improved survival outcomes.
Inmazeb (REGN-EB3 / Atoltivimab)
Approved: FDA approval October 2020 — first FDA-approved treatment for Ebola.
How it works: A cocktail of three monoclonal antibodies (atoltivimab, maftivimab, odesivimab) that bind to the Ebola virus glycoprotein and prevent cell entry.
Evidence: The PALM trial demonstrated a 29-day mortality of 33.5% with REGN-EB3 vs. 51% with ZMapp control in Zaire ebolavirus patients.[1]
⚠️ Approved for Zaire ebolavirus only. Efficacy against the novel 2026 variant is unknown.
Ebanga (Ansuvimab / mAb114)
Approved: FDA approval December 2020.
How it works: A single monoclonal antibody derived from a survivor of the 1995 DRC Ebola outbreak. Targets the receptor-binding domain of the Ebola glycoprotein.
Evidence: The PALM trial showed 29-day mortality of 35.1% with mAb114 — comparable to REGN-EB3 and superior to ZMapp.[1]
⚠️ Approved for Zaire ebolavirus only.
Advertisement
Approved Vaccines
Two vaccine products are currently approved. Both protect against Zaire ebolavirus only and have no confirmed efficacy against the novel 2026 variant.
Ervebo (rVSV-ZEBOV) — Merck
Approved: FDA approval December 2019; WHO prequalification 2019.
How it works: A live attenuated recombinant vesicular stomatitis virus (rVSV) engineered to express the Zaire ebolavirus glycoprotein.
Efficacy: The Guinea Ring Vaccination Trial showed 100% efficacy (95% CI: 63.5–100%) with no cases in vaccinated contacts vs. 23 cases in controls.[2]
Use: WHO-recommended for outbreak response in adults. Used in ring vaccination campaigns in DRC and Guinea outbreaks.
⚠️ Not effective against the novel 2026 DRC variant.
Zabdeno & Mvabea — Janssen
Approved: European Medicines Agency (EMA) approval July 2020.
How it works: A two-dose prime-boost regimen. Zabdeno (Ad26.ZEBOV) uses an adenovirus vector; Mvabea (MVA-BN-Filo) is a Modified Vaccinia Ankara vector expressing multiple filovirus antigens.
Use: Designed for pre-emptive vaccination in at-risk populations before outbreaks. The 56-day interval between doses makes it less practical for rapid outbreak response than Ervebo.
⚠️ Not approved for the novel 2026 DRC variant.
References
- Mulangu S, et al. "A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics." NEJM, 2019. doi:10.1056/NEJMoa1910993
- Henao-Restrepo AM, et al. "Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease." The Lancet, 2017. doi:10.1016/S0140-6736(16)32621-6
Frequently Asked Questions
Is there a cure for Ebola?
There is no single "cure," but two FDA-approved antiviral treatments — Inmazeb (REGN-EB3) and Ebanga (mAb114) — significantly reduce mortality from Zaire ebolavirus infections. Both are monoclonal antibody therapies that showed mortality reduction from approximately 50% down to 33–35% in the PALM trial. Neither is approved for the novel 2026 DRC variant, whose glycoprotein target has not been characterized.
Is there an Ebola vaccine?
Yes, two vaccine products are approved: Ervebo (rVSV-ZEBOV) by Merck, which showed 100% efficacy in the Guinea ring vaccination trial, and the Zabdeno/Mvabea prime-boost regimen by Janssen. Both protect against Zaire ebolavirus only. Neither is approved or validated against the novel Ebola variant identified in DRC's Ituri Province in May 2026. The WHO has initiated an Emergency Use Listing process for candidates targeting the new variant.
What is the most important treatment for Ebola?
Supportive care remains the foundation of Ebola treatment and significantly improves survival for all strains. This includes IV fluids to combat severe dehydration, electrolyte replacement, blood pressure management, treatment of secondary infections, and oxygen therapy. Early initiation of supportive care is strongly associated with improved outcomes regardless of which antiviral therapy is available.
Can antivirals treat the 2026 novel Ebola variant?
This is currently unknown. Inmazeb and Ebanga are monoclonal antibodies targeting specific epitopes of the Zaire ebolavirus glycoprotein. Their binding affinity to the novel 2026 variant's glycoprotein has not been confirmed. Emergency compassionate use of existing antivirals is being considered on a case-by-case basis for severely ill patients while research into the variant's susceptibility continues.
Clinical Reference & Reading
For healthcare workers and researchers who need deeper clinical and scientific grounding in Ebola treatment, virology, and outbreak medicine.
Disclosure: As an Amazon Associate, EbolaQuestions.com earns from qualifying purchases.
Viral Hemorrhagic Fevers — Shanta M. Zimmer & Donald S. Burke
A comprehensive clinical reference covering Ebola, Marburg, Lassa, Crimean-Congo, and all major hemorrhagic fever viruses. Covers pathophysiology, clinical management, PPE, infection control, and outbreak response. Essential for clinicians likely to encounter suspected viral hemorrhagic fever patients.
Shop on Amazon →The Hot Zone — Richard Preston
The book that first brought Ebola to public awareness. Preston's account of the 1989 Ebola Reston incident remains the most widely read narrative about a hemorrhagic fever outbreak — excellent context for anyone working in the field or explaining the disease to patients.
Shop on Amazon →Crisis in the Red Zone — Richard Preston
Preston's follow-up covering the catastrophic 2014–16 West Africa epidemic. Follows doctors and scientists through the largest Ebola outbreak in history — directly relevant context for the 2026 DRC novel variant outbreak.
Shop on Amazon →Healthcare Preparedness Products
Disclosure: As an Amazon Associate, EbolaQuestions.com earns from qualifying purchases. These recommendations are for general preparedness and informational purposes, not medical advice. Always follow institutional and public health protocols.
3M Aura N95 Respirator 9205+ (NIOSH, 20-pack)
NIOSH-approved N95 respirators provide ≥95% filtration. While Ebola is not airborne, respiratory protection is required as part of full PPE for Ebola patient care settings.
Shop N95 Masks on Amazon →Disposable Nitrile Gloves (Heavy Duty)
Double-gloving with nitrile gloves is standard in Ebola patient care. Heavy-duty nitrile provides superior chemical and puncture resistance for high-risk contact.
Shop Nitrile Gloves on Amazon →Contactless Infrared Thermometers
Fever screening at hospitals and community checkpoints is a key outbreak control measure. Contactless thermometers allow rapid screening without physical contact.
Shop Thermometers on Amazon →